Stock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates

Stock Track

May 09

Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet 6.34% during intraday trading on Friday, reflecting a sharp negative reaction from investors.

The decline followed the release of the company's fiscal second-quarter earnings report, which revealed a revenue miss that overshadowed an earnings per share beat. Arrowhead reported revenue of $73.737 million, falling short of the analyst consensus estimate of $79.991 million. While the quarterly loss of $0.93 per share beat estimates, it marked a significant deterioration from earnings of $2.75 per share in the same period last year.

Despite recent positive analyst actions, including price target raises from RBC and Chardan Capital Markets, the market focused on the disappointing top-line performance and year-over-year profit reversal, driving the stock lower.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1199808559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199808559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199808559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 00:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199808559","market":"us","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet 6.34% during intraday trading on Friday, reflecting a sharp negative reaction from investors.</p><p>The decline followed the release of the company's fiscal second-quarter earnings report, which revealed a revenue miss that overshadowed an earnings per share beat. Arrowhead reported revenue of $73.737 million, falling short of the analyst consensus estimate of $79.991 million. While the quarterly loss of $0.93 per share beat estimates, it marked a significant deterioration from earnings of $2.75 per share in the same period last year.</p><p>Despite recent positive analyst actions, including price target raises from RBC and Chardan Capital Markets, the market focused on the disappointing top-line performance and year-over-year profit reversal, driving the stock lower.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-09 00:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet 6.34% during intraday trading on Friday, reflecting a sharp negative reaction from investors.</p><p>The decline followed the release of the company's fiscal second-quarter earnings report, which revealed a revenue miss that overshadowed an earnings per share beat. Arrowhead reported revenue of $73.737 million, falling short of the analyst consensus estimate of $79.991 million. While the quarterly loss of $0.93 per share beat estimates, it marked a significant deterioration from earnings of $2.75 per share in the same period last year.</p><p>Despite recent positive analyst actions, including price target raises from RBC and Chardan Capital Markets, the market focused on the disappointing top-line performance and year-over-year profit reversal, driving the stock lower.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1199808559","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199808559","pubTimestamp":1778256637,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet 6.34% during intraday trading on Friday, reflecting a sharp negative reaction from investors.The decline followed the release of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead制药盘中暴跌6.34%Q2营收不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet 6.34% during intraday trading on Friday, reflecting a sharp negative reaction from investors.The decline followed the release of the company's fiscal second-quarter earnings report, which revealed a revenue miss that overshadowed an earnings per share beat. Arrowhead reported revenue of $73.737 million, falling short of the analyst consensus estimate of $79.991 million. While the quarterly loss of $0.93 per share beat estimates, it marked a significant deterioration from earnings of $2.75 per share in the same period last year.Despite recent positive analyst actions, including price target raises from RBC and Chardan Capital Markets, the market focused on the disappointing top-line performance and year-over-year profit reversal, driving the stock lower.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}